EGFR and lung cancer: This suggests that the proposed drugs' phytochemicals structures are likely to be more stable in the EGFR protein pocket, thus enabling them to reach their therapeutic target against breast and lung cancer cell growth with greater efficacy than Tamoxifen and Erlotinib.